TIAA CREF Investment Management LLC cut its position in Lipocine Inc. (NASDAQ:LPCN) by 4.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,110 shares of the specialty pharmaceutical company’s stock after selling 2,176 shares during the period. TIAA CREF Investment Management LLC owned about 0.27% of Lipocine worth $199,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC boosted its position in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after buying an additional 12,518 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after buying an additional 65,600 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock worth $362,000 after buying an additional 6,191 shares during the period. Hedge funds and other institutional investors own 26.39% of the company’s stock.

Lipocine Inc. (NASDAQ:LPCN) traded down 2.59% during trading on Thursday, reaching $3.58. The company had a trading volume of 284,272 shares. The company’s 50-day moving average is $4.46 and its 200 day moving average is $4.04. The firm’s market capitalization is $73.68 million. Lipocine Inc. has a 52 week low of $3.03 and a 52 week high of $5.90.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Equities analysts anticipate that Lipocine Inc. will post ($0.96) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Sells 2,176 Shares of Lipocine Inc. (LPCN)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-sells-2176-shares-of-lipocine-inc-lpcn/1534121.html.

A number of brokerages have recently commented on LPCN. Canaccord Genuity set a $11.00 target price on Lipocine and gave the stock a “buy” rating in a report on Monday, August 7th. ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Roth Capital set a $38.00 target price on Lipocine and gave the stock a “buy” rating in a report on Thursday, August 10th.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.